Optimizing tissue stewardship in non‐small cell lung cancer to support molecular characterization and treatment selection: statement from a working group of thoracic pathologists

DOI Web Site 68 References Open Access
  • Keith M Kerr
    Department of Pathology Aberdeen Royal Infirmary and Aberdeen University Medical School Aberdeen UK
  • Lukas Bubendorf
    Institute of Medical Genetics and Pathology University Hospital Basel Basel Switzerland
  • Fernando Lopez‐Rios
    Department of Pathology, 12 de Octubre University Hospital‐CIBERONC Research Institute 12 de Octubre University Hospital (i+12), Universidad Complutense Madrid Spain
  • Farah Khalil
    Moffitt Cancer Center Tampa FL USA
  • Sinchita Roy‐Chowdhuri
    The University of Texas MD Anderson Cancer Center Houston TX USA
  • Philippe Joubert
    Québec Heart and Lung Institute‐Laval University (IUCPQ‐UL) Quebec QC Canada
  • Arndt Hartmann
    Institute of Pathology University Erlangen‐Nürnberg Erlangen Germany
  • Elena Guerini‐Rocco
    Division of Pathology, IEO European Institute of Oncology IRCCS Milan Italy
  • Yasushi Yatabe
    National Cancer Center Hospital Tokyo Japan
  • Paul Hofman
    Nice University Hospital, FHU OncoAge, BB‐0033‐00025, University Côte d'Azur Nice France
  • Wendy A Cooper
    Department of Tissue Pathology and Diagnostic Oncology Royal Prince Alfred Hospital and NSW Health Pathology Sydney NSW Australia
  • Sanja Dacic
    Yale School of Medicine New Haven CT USA

Description

<jats:p>Many patients with non‐small cell lung cancer do not receive guideline‐recommended, biomarker‐directed therapy, despite the potential for improved clinical outcomes. Access to timely, accurate, and comprehensive molecular profiling, including targetable protein overexpression, is essential to allow fully informed treatment decisions to be taken. In turn, this requires optimal tissue management to protect and maximize the use of this precious finite resource. Here, a group of leading thoracic pathologists recommend factors to consider for optimal tissue management. Starting from when lung cancer is first suspected, keeping predictive biomarker testing in the front of the mind should drive the development of practices and procedures that conserve tissue appropriately to support molecular characterization and treatment selection.</jats:p>

Journal

References(68)*help

See more

Related Projects

See more

Keywords

Details 詳細情報について

Report a problem

Back to top